coenzyme-q10 and Nausea

coenzyme-q10 has been researched along with Nausea* in 2 studies

Trials

1 trial(s) available for coenzyme-q10 and Nausea

ArticleYear
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.
    Neurology, 2007, Jan-02, Volume: 68, Issue:1

    To determine if future studies of coenzyme Q(10) and GPI-1485 in Parkinson disease (PD) may be warranted.. We conducted a randomized, double-blind, calibrated futility clinical trial of coenzyme Q10 and GPI-1485 in early untreated PD using placebo data from the DATATOP study to establish the futility threshold.. The primary outcome measure (change in total Unified Parkinson's Disease Rating Scale scores over 1 year) did not meet the prespecified criteria for futility for either agent. Secondary analyses using calibration controls and other more recent placebo data question the appropriateness of the predetermined definition of futility, and suggest that a more restrictive threshold may be needed.. Coenzyme Q(10) and GPI-1485 may warrant further study in Parkinson disease, although the data are inconsistent. Additional factors (cost, availability of other agents, more recent data on placebo outcomes, other ongoing trials) should also be considered in the selection of agents for Phase III studies.

    Topics: Aged; Coenzymes; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Nausea; Parkinson Disease; Tacrolimus; Ubiquinone

2007

Other Studies

1 other study(ies) available for coenzyme-q10 and Nausea

ArticleYear
[Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:7

    This study was designed to evaluate the usefulness of Coenzyme Q10 (CoQ10) in the prevention of side effects due to anthracycline agents-Adriamycin (ADM) and Daunorubicin (DNR)-by comparing the preventive effect between CoQ10-treated and non-treated groups. The subjects were 79 patients, 55 of whom had malignant lymphoma. The age range was from 16 to 77 years with a mean age of 45.4 years. CoQ10 was administered by intravenous drip at 1 mg/kg/day the day before ADM or DNR administration, on the day and for a further 2 days after administration. In mean total dose, complete remission rate and mortality, no significant differences were observed between the 2 groups. Although there were also no significant differences in the degree of alopecia, fever, nausea and vomiting, the incidences of diarrhea and stomatitis were significantly (p less than 0.10 and p less than 0.05, respectively) reduced in the CoQ10-treated group. Depression of ST waves (more than 0.05 mV) and changes in T waves (R/10 greater than T, flat, inversion) on ECG were regarded as a parameter of aggravation. Such ECG aggravation was found in 20 of 40 patients given CoQ10 (50.0%) and in 18 of 25 receiving none (72.0%); a cardiotoxicity-inhibiting tendency was thus evident (p less than 0.10). In heart rate, tachycardia was noted in the nontreated group when the period of use of anthracycline agents exceeded 8 weeks. Twenty nine patients received ADM or DNR for 8 weeks or more, and, of them, 17 were treated with CoQ10; 11 of the 17 (64.7%) showed ECG aggravation, while 11 of 12 patients (91.7%) not treated with CoQ10 showed ECG aggravation. A tendency to depress ECG aggravation was thus observed in the treated group (p less than 0.10).

    Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Coenzymes; Daunorubicin; Diarrhea; Doxorubicin; Drug Therapy, Combination; Electrocardiography; Female; Fever; Heart Rate; Humans; Leukemia; Male; Middle Aged; Nausea; Stomatitis; Ubiquinone

1984